{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:00:05Z","timestamp":1788469205518,"version":"build-2803163510"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Refractory and relapsed Hodgkin lymphoma (R\/R HL) is associated with poor prognosis, and allogeneic stem cell transplantation (allo-SCT) remains the only potentially curative approach.<\/jats:p><jats:p><jats:bold>Aim:<\/jats:bold> The aim of the study was to evaluate the feasibility of allotransplantation in R\/R HL setting.<\/jats:p><jats:p><jats:bold>Material:<\/jats:bold> Overall, 24 patients (17 men and 7 women) at a median age of 27\u00a0years (range 18\u201344) underwent allo-SCT between 2002 and 2020.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Nineteen patients received prior autologous stem cell transplantation (ASCT1) whereas eight patients received second ASCT (ASCT2) after failure of ASCT1. Six patients received only brentuximab vedotin (BV; <jats:italic>n<\/jats:italic> = 4) or BV followed by checkpoint inhibitors (CPI; <jats:italic>n<\/jats:italic> = 2) before entering allo-SCT. Median time from ASCT1 to allo-SCT was 17.1\u00a0months. Fifteen patients received grafts from unrelated donors. Peripheral blood was a source of stem cells for 16 patients. Reduced-intensity conditioning was used for all patients. Disease status at transplant entry was as follows: complete remission (CR; <jats:italic>n<\/jats:italic> = 4), partial response (PR; <jats:italic>n<\/jats:italic> = 10), and stable disease (SD; <jats:italic>n<\/jats:italic> = 10). Acute and chronic graft-versus-host disease (GVHD) developed in 13 (54%) and 4 (16%) patients, respectively. Median follow-up for the entire cohort was 13.3\u00a0months. At the last follow-up, 17 (71%) patients died. The main causes of death were disease progression (<jats:italic>n<\/jats:italic> = 10), infectious complications (<jats:italic>n<\/jats:italic> = 6), and steroid-resistant GVHD (<jats:italic>n<\/jats:italic> = 1). Non-relapse mortality at 12\u00a0months was 25%. At the last follow-up, seven patients were alive; six patients were in CR, and one had PR. The 2-year overall survival (OS) was 40%.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Chemosensitive disease at transplant was associated with better outcome. Allo-SCT allows for long-term survival in refractory and relapsed HL.<\/jats:p>","DOI":"10.3389\/pore.2021.1609867","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T15:58:45Z","timestamp":1627401525000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center"],"prefix":"10.3389","volume":"27","author":[{"given":"A.","family":"Kopi\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kocl\u0119ga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wieczorkiewicz-Kabut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Wo\u017aniczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"W\u0142odarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"Indications for Haematopoietic Stem Cell Transplantation for Haematological Diseases, Solid Tumours and Immune Disorders: Current Practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transpl"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood-2017-09-772673","article-title":"Transplant Strategies in Relapsed\/refractory Hodgkin Lymphoma","volume":"131","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e2015015","DOI":"10.4084\/MJHID.2015.015","article-title":"Current Role of Autologous and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma","volume":"7","author":"Castagna","year":"2015","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1182\/bloodadvances.2017011130","article-title":"Should All Patients with HL Who Relapse after ASCT Be Considered for Allogeneic SCT? A Consult, Yes; a Transplant, Not Necessarily","volume":"2","author":"Moskowitz","year":"2018","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3324\/haematol.11828","article-title":"Fludarabine-melphalan as a Preparative Regimen for Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma: the Updated M.D. Anderson Cancer Center Experience","volume":"93","author":"Anderlini","year":"2008","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-Intensity Conditioning Compared with Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"Jco"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a Committee Convened to Discuss the Evaluation and Staging of Patients with Hodgkin's Disease: Cotswolds Meeting","volume":"7","author":"Lister","year":"1989","journal-title":"Jco"},{"key":"B8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised Response Criteria for Malignant Lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"Jco"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/j.bbmt.2014.06.037","article-title":"Brentuximab Vedotin Is Associated with Improved Progression-free Survival after Allogeneic Transplantation for Hodgkin Lymphoma","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.bbmt.2020.02.003","article-title":"Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse\/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain","volume":"26","author":"Mart\u00ednez","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.bbmt.2020.02.00310.1182\/blood-2016-02-699850","article-title":"Five-year Survival and Durability Results of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after PD-1 Blockade in Relapsed\/refractory Lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1182\/blood.v128.22.4571.4571","article-title":"Checkpoint Inhibitor Therapy and Graft versus Host Disease in Allogeneic Bone Marrow Transplant Recipients of Haploidentical and Matched Products with post-transplant Cyclophosphamide","volume":"128","author":"Schoch","year":"2016","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/s41375-021-01193-6","article-title":"Allogeneic Transplantation after PD-1 Blocade for Classic Hodgkin Lymphoma","volume":"5","author":"Merryman","year":"2021","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41409-019-0640-z","article-title":"Allogeneic Stem Cell Transplantation Improves Survival in Relapsed Hodgkin Lymphoma Patients Achieving Complete Remission after Salvage Treatment","volume":"55","author":"Rivas","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"B16","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1200\/JCO.1996.14.2.572","article-title":"Bone Marrow Transplants from HLA-Identical Siblings in Advanced Hodgkin's Disease","volume":"14","author":"Gajewski","year":"1996","journal-title":"Jco"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1093\/ANNONC\/MDW421","article-title":"Myeloablative versus Reduced Intensity Allogeneic Stem Cell Transplantation for Relapsed\/refractory Hodgkin's Lymphoma in Recent Years: a Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Genadieva-Stavrik","year":"2016","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1365-2141.2007.06759.x","article-title":"Reduced-intensity Conditioning for Allogeneic Haematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin Lymphoma: Impact of Alemtuzumab and Donor Lymphocyte Infusions on Long-Term Outcomes","volume":"139","author":"Peggs","year":"2007","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","article-title":"Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation Following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma","volume":"14","author":"Burroughs","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","article-title":"Post-transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: a Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"Jco"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower Graft-Versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1186\/s12885-020-07602-w","article-title":"Haploidentical Related Donor Compared to HLA-Identical Donor Transplantation for Chemosensitive Hodgkin Lymphoma Patients","volume":"20","author":"Castagna","year":"2020","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/bmt.2015.332","article-title":"Allogeneic Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: a Systematic Review and Meta-Analysis","volume":"51","author":"Rashidi","year":"2016","journal-title":"Bone Marrow Transpl"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1038\/s41409-020-0929-y","article-title":"Changes in Patients Population and Characteristics of Hematopoietic Stem Cell Transplantation for Relapsed\/refractory Hodgkin Lymphoma: an Analysis of the Lymphoma Working Party of the EBMT","volume":"55","author":"Sureda","year":"2020","journal-title":"Bone Marrow Transpl"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2021.1609867\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T15:58:47Z","timestamp":1627401527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2021.1609867\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":24,"alternative-id":["10.3389\/pore.2021.1609867"],"URL":"https:\/\/doi.org\/10.3389\/pore.2021.1609867","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,27]]},"article-number":"1609867"}}